Related Experiment Video
Updated: Mar 28, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma
Shile Zhang1, Jun S Wei2, Samuel Q Li2
1Oncogenomics Section, Genetics Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA; Program in Bioinformatics, Boston University, Boston, MA 02218, USA.
Abstract:
The molecular mechanisms underlying the aggressive behavior of MYCN driven neuroblastoma (NBL) is under intense investigation; however, little is known about the impact of this family of transcription factors on the splicing program. Here we used high-throughput RNA sequencing to systematically study the expression of RNA isoforms in stage 4 MYCN-amplified NBL, an aggressive subtype of metastatic NBL. We show that MYCN-amplified NBL tumors display a distinct gene splicing pattern affecting multiple cancer hallmark functions. Six splicing factors displayed unique differential expression patterns in MYCN-amplified tumors and cell lines, and the binding motifs for some of these splicing factors are significantly enriched in differentially-spliced genes. Direct binding of MYCN to promoter regions of the splicing factors PTBP1 and HNRNPA1 detected by ChIP-seq demonstrates that MYCN controls the splicing pattern by direct regulation of the expression of these key splicing factors. Furthermore, high expression of PTBP1 and HNRNPA1 was significantly associated with poor overall survival of stage4 NBL patients (p ≤ 0.05). Knocking down PTBP1, HNRNPA1 and their downstream target PKM2, an isoform of pro-tumor-growth, result in repressed growth of NBL cells. Therefore, our study reveals a novel role of MYCN in controlling global splicing program through regulation of splicing factors in addition to its well-known role in the transcription program. These findings suggest a therapeutically potential to target the key splicing factors or gene isoforms in high-risk NBL with MYCN-amplification.
Insights
MYCN drives aggressive neuroblastoma (NBL) by altering RNA splicing. Targeting key splicing factors like PTBP1 and HNRNPA1, regulated by MYCN, offers a potential therapeutic strategy for high-risk NBL.
Area of Science:
- Molecular Biology
- Cancer Genetics
- Transcriptomics
Background:
- MYCN amplification drives aggressive neuroblastoma (NBL).
- The role of MYCN in regulating RNA splicing remains largely unknown.
- Understanding MYCN's impact on splicing is crucial for NBL treatment.
Purpose of the Study:
- To investigate the impact of MYCN on the RNA splicing program in stage 4 NBL.
- To identify specific splicing factors and isoforms affected by MYCN.
- To explore therapeutic targets within the MYCN-driven splicing network.
Main Methods:
- High-throughput RNA sequencing of stage 4 MYCN-amplified NBL tumors and cell lines.
- ChIP-sequencing to detect MYCN binding sites.
- Differential gene expression and splicing analysis.
- Functional knockdown experiments of splicing factors and downstream targets.
Main Results:
- MYCN-amplified NBL exhibits a distinct splicing pattern impacting cancer hallmarks.
- Six splicing factors showed differential expression, with MYCN directly regulating PTBP1 and HNRNPA1.
- High expression of PTBP1 and HNRNPA1 correlated with poor patient survival.
- Knockdown of PTBP1, HNRNPA1, and PKM2 repressed NBL cell growth.
Conclusions:
- MYCN controls global RNA splicing in NBL by regulating key splicing factors.
- This study reveals a novel role for MYCN in splicing, beyond transcription.
- Targeting MYCN-regulated splicing factors presents a potential therapeutic avenue for high-risk NBL.
Related Concept Videos
RNA Splicing
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...

